MedTrace Logo

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT05824585 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2025-08-11

No results posted yet for this study

Summary

This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

DRUG

DZD8586

DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.

Sponsors & Collaborators

  • Dizal Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Tianwei Zhang · Dizal Pharma

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-15
Primary Completion
2027-04-30
Completion
2027-10-30
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05824585 on ClinicalTrials.gov